Pharvaris Outlines 2026 Strategic Priorities, Confirms NDA Filing and Key Phase 3 Data Timelines
Summary
Pharvaris N.V. detailed its 2026 strategic priorities, confirming the NDA filing for on-demand HAE treatment in 1H2026 and anticipating pivotal Phase 3 data for prophylactic HAE treatment in 3Q2026, supported by a cash runway into 1H2027.
Key Events
-
NDA Filing on Track
The company expects to file its U.S. New Drug Application (NDA) for deucrictibant as an on-demand treatment for HAE attacks in the first half of 2026, following positive results from the RAPIDe-3 Phase 3 study.
-
Pivotal Phase 3 Data Anticipated
Topline data from the CHAPTER-3 pivotal Phase 3 study of deucrictibant for prophylactic treatment of HAE attacks is expected in the third quarter of 2026.
-
AAE-C1INH Study Progress
Recruitment is ongoing in the CREAATE pivotal Phase 3 study for deucrictibant in both prophylactic and on-demand treatment of AAE-C1INH attacks.
-
Financial Runway
Pharvaris estimates its cash runway will extend into the first half of 2027, providing capital to advance its late-stage clinical programs.
Analysis
Pharvaris N.V. provided a comprehensive update on its 2026 strategic priorities, highlighting significant progress in its deucrictibant development programs for hereditary angioedema (HAE) and acquired angioedema (AAE-C1INH). The company confirmed its New Drug Application (NDA) filing for on-demand HAE treatment is on track for the first half of 2026, following positive Phase 3 RAPIDe-3 results. Additionally, topline data from the pivotal CHAPTER-3 study for prophylactic HAE treatment is anticipated in the third quarter of 2026. These milestones are critical for the company's future commercialization efforts and represent major value inflection points. The estimated cash runway into the first half of 2027 provides financial stability to execute these plans.
At the time of this filing, PHVS was trading at $25.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $11.51 to $29.80. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.